Sun Pharmaceutical Industries has dipped over 4% to Rs 576 after the US Food and Drug Administration (FDA) has issued an import alert for all products manufactured at its plant at Karkhadi, Gujarat.
The company manufactures API (Active Pharmaceutical Ingredients) and formulations at its Karkhadi unit.
An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.
The stock opened at Rs 609 and touched a low of Rs 566 on the BSE. A combined 4.2 million shares changed hands on the counter till 11000 hours on the BSE and NSE.
The company manufactures API (Active Pharmaceutical Ingredients) and formulations at its Karkhadi unit.
An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.
The stock opened at Rs 609 and touched a low of Rs 566 on the BSE. A combined 4.2 million shares changed hands on the counter till 11000 hours on the BSE and NSE.
